Psylo, a preclinical biotech firm, has raised $5 million in Seed funding as it looks to treat mental illness with naturally occurring psychedelic drugs. The fresh capital comes 12 months after the Sydney-based startup emerged Startmate‘s winter 21 cohort with an initial $1.1 million in capital from the likes Airtree’s Daniel Petre in a round led led… Read more »
Psylo, a preclinical biotech firm, has raised $1.1 million as part of an ambitious plan to treat mental illness with naturally occurring psychedelic drugs. The Sydney-based startup, part of Startmate‘s current W21 cohort, has been backed in a round led led by Chris Hitchen’s global micro-VC fund Possible Ventures. The venture’s prominent angel investors also include Airtree’s… Read more »
The Canva brand is now worth more than Woolies, Telstra and Bunnings
5 startups on what they love about working at Stone & Chalk’s innovation hubs
VC-backed crowdfunding platform Stride Equity is offering a new funding model for startups
NBN Co surfs layoff wave, cutting 500 staff to ‘simplify’ as competition grows
Daily startup news and insights, delivered to your inbox.
